{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:32:22Z","timestamp":1740130342428,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Urinary dysfunction is an adverse event of low-dose-rate brachytherapy (LDR-BT) in patients with prostate cancer. We aimed to examine the time to \u03b1-1 adrenergic antagonist withdrawal after LDR-BT initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively evaluated 1663 patients who underwent LDR-BT at our hospital during 2004\u20132022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 1485\/1663 (89.3%) patients were able to stop using \u03b1-1 adrenergic antagonists, 1111 (66.8%) of them within 1\u00a0year of LDR-BT. Risk factors for prolonged time to withdrawal were age \u226570\u00a0years, taking agents for lower urinary tract symptoms prior to LDR-BT, an International Prostate Symptom Score\u00a0\u22658, an Overactive Bladder Symptom Score\u00a0\u22653 and a residual urine volume\u00a0\u226520\u00a0ml. Of the patients who were able to stop taking \u03b1-1 adrenergic antagonists, 357\/1485 (24.0%) required resumption, 218 (61.1%) of whom did so between 1 and 3\u00a0years after LDR-BT. This period matched the period of transient worsening of the urinary symptom score. Finally, multivariable analysis identified supplemental external beam radiotherapy and an Overactive Bladder Symptom Score\u00a0\u22653 as independent risk factors for \u03b1-1 adrenergic antagonist resumption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Withdrawal of \u03b1-1 adrenergic antagonists was possible in 66.8% of patients within 1\u00a0year of LDR-BT. Our results suggest that patients who are older or have pre-treatment LUTS may have prolonged deterioration of urinary dysfunction after treatment. Resumption of \u03b1-1 adrenergic antagonists 1\u20133\u00a0years after treatment may be associated with urinary symptom flares, and close attention is necessary for patients with supplemental external beam radiotherapy and a high pretreatment Overactive Bladder Symptom Score.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae113","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T13:59:39Z","timestamp":1724853579000},"page":"1343-1350","source":"Crossref","is-referenced-by-count":0,"title":["Duration of \u03b1-1 adrenergic antagonist administration after low-dose-rate brachytherapy for prostate cancer"],"prefix":"10.1093","volume":"54","author":[{"given":"Kenta","family":"Onishi","sequence":"first","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumisato","family":"Maesaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Tomizawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Yamaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Isohashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]},{"name":"Department of Prostate Brachytherapy, Nara Medical University , 840 Shijo-cho, Kashihara, Nara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"2024121023183995600_ref1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1748-717X-8-25","article-title":"Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy","volume":"8","author":"Tanaka","year":"2013","journal-title":"Radiat Oncol"},{"key":"2024121023183995600_ref2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","article-title":"Surgery versus radiotherapy for clinically localized prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Wallis","year":"2016","journal-title":"Eur Urol"},{"key":"2024121023183995600_ref3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijrobp.2015.05.014","article-title":"Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: nationwide J-POPS Multi-Institutional Prospective Cohort Study","volume":"93","author":"Ohashi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024121023183995600_ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brachy.2014.06.008","article-title":"Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients","volume":"14","author":"Yorozu","year":"2015","journal-title":"Brachytherapy"},{"key":"2024121023183995600_ref5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0360-3016(03)00210-4","article-title":"Urinary symptom flare following I-125 prostate brachytherapy","volume":"56","author":"Cesaretti","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024121023183995600_ref6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ijrobp.2008.11.043","article-title":"Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up","volume":"75","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024121023183995600_ref7","first-page":"51","article-title":"Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer","volume":"14","author":"Onishi","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024121023183995600_ref8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12894-017-0251-1","article-title":"Assessment of lower urinary symptom flare with overactive bladder symptom score and international prostate symptom score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute","volume":"17","author":"Miyake","year":"2017","journal-title":"BMC Urol"},{"key":"2024121023183995600_ref9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/luts.12402","article-title":"Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer","volume":"14","author":"Uematsu","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"2024121023183995600_ref10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2024121023183995600_ref11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.urology.2021.12.018","article-title":"Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after 125I-brachytherapy for prostate cancer: an open-labeled, randomized, non-placebo-controlled study","volume":"161","author":"Nakai","year":"2022","journal-title":"Urology"},{"key":"2024121023183995600_ref12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.brachy.2014.09.009","article-title":"Urethral toxicity after LDR brachytherapy: experience in Japan","volume":"14","author":"Tanaka","year":"2015","journal-title":"Brachytherapy"},{"key":"2024121023183995600_ref13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13014-014-0302-7","article-title":"Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil","volume":"9","author":"Tanaka","year":"2014","journal-title":"Rad Oncol"},{"key":"2024121023183995600_ref14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.brachy.2017.12.004","article-title":"Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-a randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor","volume":"17","author":"Tanaka","year":"2018","journal-title":"Brachytherapy"},{"key":"2024121023183995600_ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.juro.2011.09.045","article-title":"Factors influencing urinary symptoms 10 years after permanent prostate seed implantation","volume":"187","author":"Stone","year":"2012","journal-title":"J Urol"},{"key":"2024121023183995600_ref16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2004.09.036","article-title":"Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study","volume":"62","author":"Elshaikh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024121023183995600_ref17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijrobp.2014.06.037","article-title":"Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals","volume":"90","author":"Keyes","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024121023183995600_ref18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.21873\/invivo.11127","article-title":"Predictive factors for prolonged urination disorder after permanent 125I brachytherapy for localized prostate cancer","volume":"31","author":"Mori","year":"2017","journal-title":"In Vivo"},{"key":"2024121023183995600_ref19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.brachy.2017.04.241","article-title":"Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score","volume":"16","author":"Sakayori","year":"2017","journal-title":"Brachytherapy"},{"key":"2024121023183995600_ref20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.brachy.2015.12.011","article-title":"Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy","volume":"15","author":"Eriguchi","year":"2016","journal-title":"Brachytherapy"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1343\/60983147\/hyae113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1343\/60983147\/hyae113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:19:06Z","timestamp":1733872746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/12\/1343\/7742925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,28]]},"published-print":{"date-parts":[[2024,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae113","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,28]]}}}